<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03652649</url>
  </required_header>
  <id_info>
    <org_study_id>maes 009</org_study_id>
    <nct_id>NCT03652649</nct_id>
  </id_info>
  <brief_title>Treatment of Type 2 Diabetes With Ketogenic Diet</brief_title>
  <official_title>Evaluation of Efficacy and Safety of Ketogenic Complete Meal Replacement as Treatment of Obesity-related Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mid-Atlantic Epilepsy and Sleep Center, LLC</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mid-Atlantic Epilepsy and Sleep Center, LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of ketogenic diet (KD)&#xD;
      complete meal replacement treatment of obesity-related Type 2 diabetes mellitus (T2DM) and of&#xD;
      obesity in patients with obesity and T2DM. This will be an open-label single arm study&#xD;
      evaluating glycemic control and weight loss in obese participants with type 2 diabetes&#xD;
      treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day diet.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of the study is to evaluate the efficacy and safety of ketogenic diet (KD)&#xD;
      complete meal replacement treatment of obesity-related Type 2 diabetes mellitus (T2DM) and of&#xD;
      obesity in patients with obesity and T2DM. This will be an open-label single arm study&#xD;
      evaluating glycemic control and weight loss in obese participants with type 2 diabetes&#xD;
      treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day diet.&#xD;
&#xD;
      Treatment will consist of KD complete meal replacement with 3:1 [fat]: [protein +&#xD;
      carbohydrate] weight ratio, and with 1600 kcal restriction. It will consist of pre-made&#xD;
      meals, including breakfast, lunch, dinner and two snacks, one each between breakfast and&#xD;
      lunch and lunch and dinner. Meals will be made according to supplied recipes (Anemone, LLC.)&#xD;
      with a 3-week long meal plan consisting of different recipes for the 3 meals and 2 snacks&#xD;
      different for each day of the 3-week cycle, with repeating cycles. All KD-treated&#xD;
      participants will receive the same meal plan. Meals will be prepared uniformly by one&#xD;
      facility and will be delivered to participants frozen once a week in packages subdivided into&#xD;
      individual days with each day's package containing 5 separately packaged meals. Participants&#xD;
      will be given a list of allowed 0 calories drinks and will consume no non-allowed beverages.&#xD;
      Reductions to oral glycemic medications will occur at the start of the diet.&#xD;
&#xD;
      Participants will be evaluated in face-to-face visit during weeks 1, 2 and 4 of the study,&#xD;
      then monthly (see Table 1, visit schedule). Evaluations will include weight, BMI, BP, waist&#xD;
      circumference, adverse events and treatment compliance. Participants will check their blood&#xD;
      glucose levels 3x/day, including am fasting, mid-day and evening 2 hours post-prandial, and&#xD;
      urine for ketones levels with Ketostix (Bayer AG, IN, U.S.A.) 2x/day. They will record&#xD;
      results in a glucose and ketone level diary which will be reviewed at each visit. Laboratory&#xD;
      evaluations will include 8 am serum fasting glucose, insulin levels, C-peptide and lipid&#xD;
      panel, HbA1C, serum beta-hydroxybutyrate (BOH), leptin levels, C-reactive protein (CRP),&#xD;
      complete blood count (CBC), basic metabolic profile (BMP), renal and liver functions tests&#xD;
      (LFTs), and uric acid. Laboratory evaluations will be obtained once at baseline prior to&#xD;
      treatment initiation, at 3 and 6 months after treatment initiation. Hunger will be evaluated&#xD;
      with a 7-point Likert scale (range: extremely hungry to extremely full) which will be&#xD;
      administered at each visit.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Anticipated">November 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">November 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Type 2 diabetes remission</measure>
    <time_frame>6 months (study duration)</time_frame>
    <description>Defined as normal fasting blood glucose (&lt;126), normal HbA1C (&lt;6.4%), and no diabetic medications</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in glucose blood level in patients with type 2 DM in 6 months.</measure>
    <time_frame>6 months (study duration)</time_frame>
    <description>Defined as normal fasting blood glucose (&lt;126), normal HbA1C (&lt;6.4%), and no diabetic medications</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of diabetic medication load reduction</measure>
    <time_frame>6 months (study duration)</time_frame>
    <description>Change in diabetic medication load</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in HbA1C in patients with type 2 DM in 6 months.</measure>
    <time_frame>0, 3 and 6 months treatment duration</time_frame>
    <description>HbA1C</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events</measure>
    <time_frame>6 months (study duration)</time_frame>
    <description>Adverse events occurrence</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting serum insulin</measure>
    <time_frame>0, 3 and 6 months treatment duration</time_frame>
    <description>Change in fasting serum insulin value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BMI</measure>
    <time_frame>Day 0, Day 7, Day 14, Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Change BMI from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Weight</measure>
    <time_frame>Day 0, Day 7, Day 14, Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Change weight from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Waist circumference</measure>
    <time_frame>Day 7, Day 14, Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Change waist circumference from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Day 7, Day 14, Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Change of systolic and diastolic blood pressures from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urine ketone levels</measure>
    <time_frame>Day 7, Day 14, Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Urine ketone levels evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting leptin levels</measure>
    <time_frame>0, 3 and 6 months treatment duration</time_frame>
    <description>Fasting leptin levels evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fasting lipid levels</measure>
    <time_frame>0, 3 and 6 months treatment duration</time_frame>
    <description>Fasting lipid levels evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hunger scale scores</measure>
    <time_frame>Day 0, Day 7, Day 14, Month 1, 2, 3, 4, 5 and 6</time_frame>
    <description>Likert scale (range: extremely hungry to extremely full) which will be administered at each visit.The best outcome is 5=satisfied.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Type2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>3:1 Ketogenic Complete Meal Replacement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Evaluating glycemic control and weight loss in obese participants with type 2 diabetes treated for 6 months with 3:1 [fat]:[protein+carbohydrate] ratio, 1600 kcal/day complete meal replacement ketogenic diet</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>3:1 ratio Ketogenic diet</intervention_name>
    <description>Type 2 Diabetic subjects with BMI greater than or equal to 30 are started on 3:1 ratio ketogenic complete meal replacement program and weight loss and glycemic control is tracked over 6 month intervention period</description>
    <arm_group_label>3:1 Ketogenic Complete Meal Replacement</arm_group_label>
    <other_name>Classic Ketogenic Diet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-70&#xD;
&#xD;
          2. Ability and willingness to sign informed consent form.&#xD;
&#xD;
          3. T2D with BMI ≥ 30 kg/m2&#xD;
&#xD;
          4. Stable hypoglycemic medications for at least 2 months&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of bariatric surgery ≤ 2 years prior to enrollment.&#xD;
&#xD;
          2. Any systemic illness or unstable medical condition that might pose additional risk,&#xD;
             including: cardiac, unstable metabolic or endocrine disturbances, renal or liver&#xD;
             disease, past history of renal calculi, hyperuricemia, hypercalcemia, mitochondrial&#xD;
             disease, known disorder of fatty acid metabolism, porphyria, and active systemic&#xD;
             cancer.&#xD;
&#xD;
          3. History of uncontrolled hyperlipidemia&#xD;
&#xD;
          4. Change in the dose or type of hypoglycemic treatment within 1 month prior to&#xD;
             enrollment.&#xD;
&#xD;
          5. Psychosis within six months of enrollment, evidenced by treatment with anti-psychotic&#xD;
             medications with recent medication initiation or dose increase.&#xD;
&#xD;
          6. Active drug or alcohol dependence or any other factors that, in the opinion of the&#xD;
             site investigators would interfere with adherence to study requirements;&#xD;
&#xD;
          7. History of cerebrovascular disease or unstable heart disease within 6 months of&#xD;
             enrollment&#xD;
&#xD;
          8. Pregnancy&#xD;
&#xD;
          9. Use of any investigational drugs within 3 months of enrollment.&#xD;
&#xD;
         10. Inability or unwillingness of subject to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pavel Klein, M.B,B.Chir.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mid-Atlantic Epilepsy and Sleep Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ivana Tyrlikova</last_name>
    <phone>3015309744</phone>
    <email>tyrlikovai@epilepsydc.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lenka Goldman</last_name>
    <phone>3015309744</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ivana Tyrlikova</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ivana Tyrlikova, MD</last_name>
      <phone>301-530-9744</phone>
      <email>tyrlikovai@epilepsydc.com</email>
    </contact>
    <contact_backup>
      <last_name>Pavel Klein, MD</last_name>
      <phone>3015309744</phone>
      <email>kleinp@epilepsydc.com</email>
    </contact_backup>
    <investigator>
      <last_name>Pavel Klein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>July 5, 2018</study_first_submitted>
  <study_first_submitted_qc>August 28, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2018</study_first_posted>
  <last_update_submitted>August 28, 2018</last_update_submitted>
  <last_update_submitted_qc>August 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 29, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Mid-Atlantic Epilepsy and Sleep Center, LLC</investigator_affiliation>
    <investigator_full_name>Pavel Klein</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>diabetes</keyword>
  <keyword>ketogenic diet</keyword>
  <keyword>low carb diet</keyword>
  <keyword>weight loss</keyword>
  <keyword>obesity</keyword>
  <keyword>diet treatment</keyword>
  <keyword>nutrition</keyword>
  <keyword>BMI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

